Reni Benjamin

Edward Tenthoff

Leland Gershell

Maurice Raycroft

Stephen Willey

Ted Tenthoff

- Cue Biopharma, Inc. announced the appointment of **Usman Azam** as President and Chief Executive Officer and a member of the Board of Directors, effective **September 29, 2025**.  **[1645460_0000950130-25-000140_cue-20250926.htm:1]** 
- Dr. Azam succeeds **Daniel R. Passeri**, who retired and resigned from his roles as CEO and Board member, also effective **September 29, 2025**.  **[1645460_0000950130-25-000140_cue-20250926.htm:1]** 
- Dr. Azam's compensation package includes an annual base salary of **$620,000**, eligibility for a discretionary incentive bonus of up to **50% of his base salary**, and stock options to purchase a total of **2,250,000 shares** (1,875,000 time-based and 375,000 performance-based).  **[1645460_0000950130-25-000140_cue-20250926.htm:1]** 
- In connection with his departure, Mr. Passeri will receive a lump sum cash severance payment of **$838,750** and continued COBRA payments for up to **18 months**.  **[1645460_0000950130-25-000140_cue-20250926.htm:3]**  He will also serve as a strategic advisor until **March 30, 2026**, and will be granted a stock option to purchase up to **375,000 shares**.  **[1645460_0000950130-25-000140_cue-20250926.htm:3]** **[1645460_0000950130-25-000140_cue-20250926.htm:4]**

Cue Biopharma (CUE)